1. Market Research
  2. > All Companies
  3. > Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2015

Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 229 pages

Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2015’, provides an overview of the Takeda Pharmaceutical Company Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Takeda Pharmaceutical Company Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Takeda Pharmaceutical Company Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Takeda Pharmaceutical Company Limited’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Takeda Pharmaceutical Company Limited’s pipeline products

Reasons to buy

- Evaluate Takeda Pharmaceutical Company Limited’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Takeda Pharmaceutical Company Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Takeda Pharmaceutical Company Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Takeda Pharmaceutical Company Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Takeda Pharmaceutical Company Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Takeda Pharmaceutical Company Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Takeda Pharmaceutical Company Limited Snapshot 7
Takeda Pharmaceutical Company Limited Overview 7
Key Information 7
Key Facts 7
Takeda Pharmaceutical Company Limited - Research and Development Overview 8
Key Therapeutic Areas 8
Takeda Pharmaceutical Company Limited - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Combination Treatment Modalities 16
Pipeline Products - Partnered Products 17
Pipeline Products - Out-Licensed Products 19
Takeda Pharmaceutical Company Limited - Pipeline Products Glance 21
Takeda Pharmaceutical Company Limited - Late Stage Pipeline Products 21
Takeda Pharmaceutical Company Limited - Clinical Stage Pipeline Products 24
Takeda Pharmaceutical Company Limited - Early Stage Pipeline Products 27
Takeda Pharmaceutical Company Limited - Drug Profiles 31
(alogliptin benzoate + metformin hydrochloride) 31
(alogliptin benzoate + pioglitazone hydrochloride) 33
alogliptin benzoate 35
ceftaroline fosamil 38
glatiramer acetate 40
haemophilus influenzae [serotype B] vaccine 42
ramelteon 43
roflumilast 44
vedolizumab 47
(amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) 49
azilsartan medoxomil 50
febuxostat XR 52
immune globulin (human) 53
rasagiline mesylate 55
trebananib 56
vortioxetine hydrobromide 59
risedronate sodium 62
AM-4 63
DSM-265 64
MLN-1202 66
motesanib diphosphate 68
namilumab 72
relugolix 74
TAK-003 75
TAK-063 78
TAK-114 79
TAK-214 81
TAK-272 83
TAK-850 84
fulranumab 86
TAK-020 89
TAK-021 90
TAK-058 91
TAK-079 92
TAK-233 93
TAK-648 94
TAK-915 95
TAK-935 96
tedatioxetine 97
BTZO-15 99
BTZO-2 100
chikungunya vaccine 101
ELQ-300 103
influenza [strain H5N1] vaccine 104
influenza vaccine 105
mapatumumab 106
modified vaccinia ankara vaccine 108
Monoclonal Antibody Conjugate for Cancer 109
Monoclonal Antibody Conjugated to Target c-Ret for Breast Cancer 110
respiratory syncytial virus vaccine 111
rotavirus vaccine 112
RUSKI-43 113
Small Molecule to Activate Glucokinase for Type 2 Diabetes 115
Small Molecule to Agonize Cannabinoid Receptor for Inflammatory Pain 116
Small Molecule to Agonize GPR52 for Psychiatry Disorders 117
Small Molecule to Antagonize Androgen Receptor for Prostate Cancer 118
Small Molecule to Antagonize Mineralocorticoid Receptor for Hypertension 119
Small Molecule to Antagonize Neurokinin-1 Receptor for Overactive Bladder 120
Small Molecule to Antagonize PDGFR and VEGFR-2 for Cancer 121
Small Molecule to Inhibit BTK for Rheumatoid Arthritis 122
Small Molecule to Inhibit Dopamine Transporter, Noradrenaline Transporter and Serotonin Transporter for Depression 123
Small Molecule to Inhibit FAAH for Pain 124
Small Molecule to Inhibit Farnesoid X Receptor for Dyslipidemia 125
Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease 126
Small Molecule to Inhibit HER2/EGFR for Cancer 127
Small Molecule to Inhibit MCHR1 for Obesity 128
Small Molecule to Inhibit Serotonin-Norepinephrine-Dopamine Reuptake for Depression 129
Small Molecules for Cognitive Impairment Associated with Schizophrenia 130
Small Molecules for Parkinson's Disease 131
Small Molecules for Visceral Leishmaniasis 132
Small Molecules to Agonize GPR119 for Type II Diabetes 133
Small Molecules to Antagonize c-Met and VEGFR2 for Cancer 134
Small Molecules to Inhibit Acetyl-CoA Carboxylase for Obesity 135
Small Molecules to Inhibit CENP-E for Cancer 136
Small Molecules to Inhibit DPP-IV for Type 2 Diabetes 137
Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma 138
Small Molecules to Inhibit PARP-1 for Cancer 139
Stem Cell Therapy for Muscular Dystrophy 140
T-1840383 141
T-3256336 142
TAK-075 143
TAK-480 144
TAK-632 145
TAK-792 146
Y-443 147
Antibodies for Undisclosed Indication 148
Drug to Inhibit PDE for Leishmaniasis and Trypanosomiasis 149
Small Molecule for Undisclosed Indication 150
Small Molecule to Inhibit Arginine Methyltrasferase for Cancer 151
Small Molecule to Inhibit FAK for Cancer 152
Small Molecule to Inhibit HDAC6 for Undisclosed Indication 153
Small Molecule to Inhibit HER2 and EGFR for Cancer 154
Small Molecule to Inhibit IAP for Cancer 155
Small Molecules for Malaria 156
Small Molecules for Tuberculosis 157
Small Molecules to Inhibit Apoptosis Signal-Regulating Kinase 1 for Undisclosed Indication 158
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Cancer 159
Small Molecules to Inhibit MMP-13 for Osteoarthritis 160
Y-142 161
Takeda Pharmaceutical Company Limited - Pipeline Analysis 162
Takeda Pharmaceutical Company Limited - Pipeline Products by Target 162
Takeda Pharmaceutical Company Limited - Pipeline Products by Route of Administration 168
Takeda Pharmaceutical Company Limited - Pipeline Products by Molecule Type 169
Takeda Pharmaceutical Company Limited - Pipeline Products by Mechanism of Action 170
Takeda Pharmaceutical Company Limited - Recent Pipeline Updates 175
Takeda Pharmaceutical Company Limited - Dormant Projects 197
Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products 200
Discontinued Pipeline Product Profiles 201
Takeda Pharmaceutical Company Limited - Company Statement 210
Takeda Pharmaceutical Company Limited - Locations And Subsidiaries 211
Head Office 211
Other Locations and Subsidiaries 211
Takeda Pharmaceutical Company Limited - Key Manufacturing Facilities 219
Appendix 220
Methodology 220
Coverage 220
Secondary Research 220
Primary Research 220
Expert Panel Validation 220
Contact Us 220
Disclaimer 221

List of Tables
Takeda Pharmaceutical Company Limited, Key Information 15
Takeda Pharmaceutical Company Limited, Key Facts 15
Takeda Pharmaceutical Company Limited - Pipeline by Indication, 2015 17
Takeda Pharmaceutical Company Limited - Pipeline by Stage of Development, 2015 22
Takeda Pharmaceutical Company Limited - Monotherapy Products in Pipeline, 2015 23
Takeda Pharmaceutical Company Limited - Combination Treatment Modalities in Pipeline, 2015 24
Takeda Pharmaceutical Company Limited - Partnered Products in Pipeline, 2015 25
Takeda Pharmaceutical Company Limited - Partnered Products/ Combination Treatment Modalities, 2015 26
Takeda Pharmaceutical Company Limited - Out-Licensed Products in Pipeline, 2015 27
Takeda Pharmaceutical Company Limited - Out-Licensed Products/ Combination Treatment Modalities, 2015 28
Takeda Pharmaceutical Company Limited - Pre-Registration, 2015 29
Takeda Pharmaceutical Company Limited - Filing rejected/Withdrawn, 2015 30
Takeda Pharmaceutical Company Limited - Phase III, 2015 31
Takeda Pharmaceutical Company Limited - Phase II, 2015 32
Takeda Pharmaceutical Company Limited - Phase I, 2015 34
Takeda Pharmaceutical Company Limited - Preclinical, 2015 35
Takeda Pharmaceutical Company Limited - Discovery, 2015 38
Takeda Pharmaceutical Company Limited - Pipeline by Target, 2015 170
Takeda Pharmaceutical Company Limited - Pipeline by Route of Administration, 2015 176
Takeda Pharmaceutical Company Limited - Pipeline by Molecule Type, 2015 177
Takeda Pharmaceutical Company Limited - Pipeline Products by Mechanism of Action, 2015 178
Takeda Pharmaceutical Company Limited - Recent Pipeline Updates, 2015 183
Takeda Pharmaceutical Company Limited - Dormant Developmental Projects,2015 205
Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products, 2015 208
Takeda Pharmaceutical Company Limited, Subsidiaries 219
Takeda Pharmaceutical Company Limited, Key Manufacturing Facilities 227

List of Figures
Takeda Pharmaceutical Company Limited - Pipeline by Top 10 Indication, 2015 17
Takeda Pharmaceutical Company Limited - Pipeline by Stage of Development, 2015 22
Takeda Pharmaceutical Company Limited - Monotherapy Products in Pipeline, 2015 23
Takeda Pharmaceutical Company Limited - Combination Treatment Modalities in Pipeline, 2015 24
Takeda Pharmaceutical Company Limited - Partnered Products in Pipeline, 2015 25
Takeda Pharmaceutical Company Limited - Out-Licensed Products in Pipeline, 2015 27
Takeda Pharmaceutical Company Limited - Pipeline by Top 10 Target, 2015 170
Takeda Pharmaceutical Company Limited - Pipeline by Top 10 Route of Administration, 2015 176
Takeda Pharmaceutical Company Limited - Pipeline by Top 10 Molecule Type, 2015 177
Takeda Pharmaceutical Company Limited - Pipeline Products by Top 10 Mechanism of Action, 2015 178

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2016

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2016

  • $ 2 500
  • Company report
  • February 2016
  • by Global Data

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2016 Summary GlobalData's clinical trial report, “Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2016" provides an overview ...

Alzheimer’s Disease - Pipeline Review, H1 2016

Alzheimer’s Disease - Pipeline Review, H1 2016

  • $ 2 500
  • Company report
  • March 2016
  • by Global Markets Direct

Alzheimer’s Disease - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Alzheimer’s Disease - Pipeline Review, H1 2016’, provides an overview of the Alzheimer’s Disease pipeline landscape. ...

Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2016

Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2016

  • $ 2 500
  • Company report
  • February 2016
  • by Global Data

Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2016 Summary GlobalData's clinical trial report, “Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2016" provides an overview of ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.